Join
Live feed
·
PRReleasevia Quantisnow
Opus Genetics Inc. logo

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

ByQuantisnow·Wall Street's wire, on your screen.
IRD· Opus Genetics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IRD (Opus Genetics Inc.) and more on Quantisnow.